332 related articles for article (PubMed ID: 1832384)
1. CD3+ T cells in severe combined immunodeficiency (scid) mice. IV. Graft-vs.-host resistance of H-2d scid mice to intravenous injection of allogeneic H-2b (C57BL/6) spleen cells.
Claesson MH; Rudolphi A; Tscherning T; Reimann J
Eur J Immunol; 1991 Sep; 21(9):2057-62. PubMed ID: 1832384
[TBL] [Abstract][Full Text] [Related]
2. CD3+ T cells in severe combined immunodeficiency (scid) mice. II. Transplantation of dm2 lymphoid cells into semi-allogeneic scid mice.
Rudolphi A; Spiess S; Conradt P; Claesson MH; Reimann J
Eur J Immunol; 1991 Jul; 21(7):1591-600. PubMed ID: 1829409
[TBL] [Abstract][Full Text] [Related]
3. CD3+ T cells in severe combined immunodeficiency (SCID) mice. V. Allogeneic T cells engrafted into SCID mice do not induce graft-versus-host disease in spite of the absence of host veto and natural suppressor cell activity.
Tscherning T; Rudolphi A; Reimann J; Claesson MH
Scand J Immunol; 1991 Dec; 34(6):795-801. PubMed ID: 1836277
[TBL] [Abstract][Full Text] [Related]
4. CD3+ T cells in severe combined immune deficiency (scid) mice. I. Transferred purified CD4+ T cells, but not CD8+ T cells are engrafted in the spleen of congenic scid mice.
Rudolphi A; Spiess S; Conradt P; Claësson MH; Reimann J
Eur J Immunol; 1991 Feb; 21(2):523-33. PubMed ID: 1671840
[TBL] [Abstract][Full Text] [Related]
5. Effect of graft-versus-host disease on anti-tumor immunity.
Schreiber KL; Forman J
J Immunol; 1990 Mar; 144(5):2018-26. PubMed ID: 1968493
[TBL] [Abstract][Full Text] [Related]
6. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
Drobyski WR; Majewski D; Hanson G
Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
Drobyski WR; Majewski D; Ozker K; Hanson G
J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
[TBL] [Abstract][Full Text] [Related]
8. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens.
Cohen P; Vourka-Karussis U; Weiss L; Slavin S
J Immunol; 1993 Nov; 151(9):4803-10. PubMed ID: 8409438
[TBL] [Abstract][Full Text] [Related]
9. Studies of immunologic tolerance to host minor histocompatibility antigens following allogeneic bone marrow transplantation in mice.
Perreault C; Allard A; Brochu S; Poupart C; Fontaine P; Bélanger R; Gyger M
Bone Marrow Transplant; 1990 Aug; 6(2):127-35. PubMed ID: 2145050
[TBL] [Abstract][Full Text] [Related]
10. Role of L3T4+ and Lyt-2+ donor cells in graft-versus-host immune deficiency induced across a class I, class II, or whole H-2 difference.
Moser M; Sharrow SO; Shearer GM
J Immunol; 1988 Apr; 140(8):2600-8. PubMed ID: 3258615
[TBL] [Abstract][Full Text] [Related]
11. Reactivity of hybridomas derived from T cells activated in vivo during graft-versus-host disease.
Leibnitz RR; Lipsky PE; Thiele DL
J Immunol; 1994 Dec; 153(11):4959-68. PubMed ID: 7963559
[TBL] [Abstract][Full Text] [Related]
12. Prevention of lethal graft-versus-host disease in mice by monoclonal antibodies directed against T cells or their subsets. I. Evidence for the induction of a state of tolerance based on suppression.
Knulst AC; Tibbe GJ; Noort WA; Bril-Bazuin C; Benner R; Savelkoul HF
Bone Marrow Transplant; 1994 Mar; 13(3):293-301. PubMed ID: 8199571
[TBL] [Abstract][Full Text] [Related]
13. Regional oral tolerance in transgenic 2C mice.
Margenthaler JA; Flye MW
Surgery; 2005 Aug; 138(2):141-9. PubMed ID: 16153420
[TBL] [Abstract][Full Text] [Related]
14. Role of cytotoxic T lymphocytes in the prevention of lupus-like disease occurring in a murine model of graft-vs-host disease.
Via CS; Sharrow SO; Shearer GM
J Immunol; 1987 Sep; 139(6):1840-9. PubMed ID: 2957440
[TBL] [Abstract][Full Text] [Related]
15. Selective engraftment of memory CD4+ T cells with an unusual recirculation pattern and a diverse T cell receptor-V beta repertoire into scid mice.
Reimann J; Rudolphi A; Tscherning T; Claesson MH
Eur J Immunol; 1993 Feb; 23(2):350-6. PubMed ID: 8094671
[TBL] [Abstract][Full Text] [Related]
16. Tumor allograft rejection is mainly mediated by CD8+ cytotoxic T lymphocytes stimulated with class I alloantigens in cooperation with CD4+ helper T cells recognizing class II alloantigens.
Tomita Y; Mayumi H; Eto M; Nomoto K
J Immunol; 1990 Mar; 144(6):2425-35. PubMed ID: 1968930
[TBL] [Abstract][Full Text] [Related]
17. Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens.
Jones SC; Friedman TM; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2004 Feb; 10(2):91-105. PubMed ID: 14750075
[TBL] [Abstract][Full Text] [Related]
18. Amelioration of acute graft-versus-host disease and re-establishment of tolerance by short-term treatment with an anti-TCR antibody.
Maeda T; Eto M; Lin T; Nishimura Y; Kong YY; Nomoto K; Nomoto K
J Immunol; 1994 Nov; 153(9):4311-20. PubMed ID: 7930630
[TBL] [Abstract][Full Text] [Related]
19. Immunization with soluble simian virus 40 large T antigen induces a specific response of CD3+ CD4- CD8+ cytotoxic T lymphocytes in mice.
Schirmbeck R; Zerrahn J; Kuhröber A; Kury E; Deppert W; Reimann J
Eur J Immunol; 1992 Mar; 22(3):759-66. PubMed ID: 1312473
[TBL] [Abstract][Full Text] [Related]
20. Prevention of graft-versus-host disease by a novel immunosuppressant, (5R)-5-hydroxytriptolide (LLDT-8), through expansion of regulatory T cells.
Tang W; Yang Y; Zhang F; Li YC; Zhou R; Wang JX; Zhu YN; Li XY; Yang YF; Zuo JP
Int Immunopharmacol; 2005 Dec; 5(13-14):1904-13. PubMed ID: 16275625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
